MDXG
MiMedx Group, Inc.
Biotechnology · Healthcare · United States
4.50
close · 2026-08-28
value
66
cheaper than peers66
quality
68
stronger fundamentals68
ranked against
Biotechnology (commercial)
value
quality
151 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.78× | 93 |
| price to book | 3.04× | 65 |
| forward P/E | 22.50× | 49 |
| EV to EBITDA | 24.89× | 42 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | 2.9% | 82 |
| operating margin | -28.7% | 68 |
| debt to equity | 8.0% | 67 |
| revenue growth | -34.7% | 25 |
4 of 4 measures available
Facts
| market cap | $656M |
| free cash flow | $41.4M |
| employees | 808 |
| first trade | 2008-02-12 |
| next earnings | 2026-07-29 |
| fundamentals updated | 2026-08-21 |